Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arbaclofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 8/20 | 0.96 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 8/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | THRB | P10828 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | DRD3 | P35462 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Baclofen SCHEMBL656539 | 1.00 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19334 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL351220 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19333 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL5556250 | 0.98 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL4915007 | 0.96 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL20815463 | 0.95 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL2996117 | 0.95 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL3004536 | 0.95 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL22352888 | 0.92 | GABBR2 (0.87) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298730-B1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8791295-B2 | Method of producing purified optically acitve 4-amino-3-(substituted phenyl)butanoic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8344028-B2 | Gamma-amino-butyric acid derivatives as GABAB receptor ligands | XENOPORT, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8293926-B2 | Method of producing optically active 4-amino-3-substituted phenylbutanoic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110087049-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-04-14 | — | — | US | disclosed |
| EP-2298730-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010120370-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20090137819-A1 | Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-0651736-B1 | PROCESS FOR PREPARING ENANTIOMER-PURE beta-SUBSTITUTED gamma-AMINOBUTYRIC ACID DERIVATES, NEW ENANTIOMER-PURE INTERMEDIATE STAGES OF SAID PROCESS AND THEIR USE | HERDEIS CLAUS (DE) | 1998-01-14 | — | — | EP | disclosed |
| EP-0651736-A1 | PROCESS FOR PREPARING ENANTIOMER-PURE -SUBSTITUTED gamma-AMINOBUTYRIC ACID DERIVATES, NEW ENANTIOMER-PURE INTERMEDIATE STAGES OF SAID PROCESS AND THEIR USE | HERDEIS, Claus (DE) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002443-A2 | PROCESS FOR PREPARING ENANTIOMER-PURE β-SUBSTITUTED η-AMINOBUTYRIC ACID DERIVATES, NEW ENANTIOMER-PURE INTERMEDIATE STAGES OF SAID PROCESS AND THEIR USE | HERDEIS CLAUS (DE) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | GABBR2 4/4885GABBR1 5/4885LMNA 3900/4885 |
| US-20090137819-A1 | Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid | ALAD, ATP6V1B1, DAO | GABBR2 36/4885GABBR1 77/4885LMNA 2454/4885 |
| US-20110087049-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | ALAD, OR10J3, ACMSD | GABBR2 44/4885GABBR1 41/4885LMNA 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.